U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
FDA priority review for Enspryng in MOGAD, an autoimmune disease with no approved treatments.
What changed
FDA priority review for Enspryng in MOGAD, an autoimmune disease with no approved treatments.
Why it matters
FDA priority review for Enspryng in MOGAD, an autoimmune disease with no approved treatments. — impact context not separately stored; see What changed.
← Dashboard
Sep 10, 2026 05:49 AM ET